Antagna yttranden och tidigare samråd om tillståndsansökningar

Antagna yttranden och tidigare samråd om tillståndsansökningar

Antagna yttranden och tidigare samråd om tillståndsansökningar

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid. 

 

There are currently no ongoing consultations.
 
0166-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Rousselot bvba Use of 4-(1,1,3,3-tetramethylbutyl)phenol ethoxylated as a surfactant in the manufacturing of low endotoxin gelatin Commission decided Details
0177-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Rentschler Biopharma SE Use of 4-(1,1,3,3-tetramethylbutyl) phenol, ethoxylated in a washing buffer applied during a purification step in the manufacture of the monoclonal antibody Dinutuximab beta Commission decided Details
0170-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Octapharma AB
Octapharma Pharmazeutika Produktionsgesellschaft m.b.H
Octapharma S.A.S.
Octapharma Produktionsgesellschaft Deutschland mbH
Use of 4-(1,1,3,3-tetramethylbutyl) phenol, ethoxylated as detergent for a virus inactivation step (solvent/detergent treatment) during the manufacture of plasma-derived and recombinant medicinal products Commission decided Details
0170-02 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Octapharma AB Use of 4-(1,1,3,3-tetramethylbutyl) phenol, ethoxylated as component of a chromatography column regeneration solution during the manufacture of a recombinant-derived Factor VIII Commission decided Details
0162-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Novo Nordisk A/S Use of 4-(1,1,3,3-tetramethylbutyl) phenol, ethoxylated as a solvent/detergent agent for virus inactivation in the manufacture of pharmaceutical products used in the treatment of rare bleeding disorders. Commission decided Details
0139-02 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Ortho-Clinical Diagnostics France [application transferred from: “Ortho-Clinical Diagnostics” due to a notified legal entity change]. Use of 4-(1,1,3,3-Tetramethylbutyl) phenol, ethoxylated (as Triton X-100) in two in vitro diagnostic VITROS® products used by professional diagnostic laboratories to detect antibodies to human hepatitis A virus and IgG antibodies to rubella virus. Commission decided Details
0163-02 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Wallac Oy Use of 4-(1,1,3,3-Tetramethylbutyl) phenol, ethoxylated (as Triton X-100) in enhancement solutions and DELFIA standard and maintenance solutions as a critical ingredient for detection process while measuring europium (or other lanthanide) content in In Vitro Diagnostic assays and RUO products or during maintenance of instruments Commission decided Details
0178-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Takeda Manufacturing Austria AG [name of the applicant in the original application: Baxter AG updated due to a change of corporate name]; Baxalta Belgium Manufacturing SA Use of 4-(1,1,3,3-tetramethylbutyl) phenol, ethoxylated (as a detergent) for virus inactivation via S/D (Solvent/Detergent) treatment in recombinant and plasma-derived medicinal products. Commission decided Details
0195-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - RSI ChemRep Europe Ltd (O002) OR for OraSure Technologies Inc Use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated as surfactant in in –vitro diagnostic device developer solution. Commission decided Details
0259-01 Initial Chromium trioxide 215-607-8 1333-82-0 MT METAL TECH S.r.l. [application transferred from “ST SRL” due to a notified legal entity change] Use for electroplating of different types of substrates with the purpose to create a long-lasting high durability surface with bright (shiny) or matte look (functional electroplating with decorative character) Opinions adopted Details
0237-01 Initial Chromium trioxide 215-607-8 1333-82-0 Carlo Nobili SPA Rubinetterie Use at industrial site electroplating of different types of substrates to achieve functional surfaces with high durability and a bright or matt silvery appearance for sanitary applications Opinions adopted Details
0176-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - LFB BIOMEDICAMENTS Use as virus inactivation into the manufacture process of plasma-derived immunoglobulins. Commission decided Details
0029-01 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 Laboratoires Expanscience Use as process and extracting solvent in the manufacture of plant-derived pharmaceutical bioactive ingredients Commission decided Details
0239-01 initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Prionics Lelystad B.V Use as component of buffer solutions to produce antigens (Cell extraction, cell lysis, coating of biological antigens onto articles, inactivation of microorganisms that produce targeted antigen and solvent exchange) and in-process and final Quality Control of antigens intended for use as veterinary and human health laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications Commission decided Details
0239-02 Initial 4-Nonylphenol, branched and linear, ethoxylated - - Prionics Lelystad B.V. Use as component of buffer solutions to produce antigens (Cell extraction, cell lysis, coating of biological antigens onto articles, inactivation of microorganisms that produce targeted antigen and solvent exchange) and in-process and final Quality Control of antigens intended for use as veterinary and human health laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications Commission decided Details
0206-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Phadia GmbH; Thermo Fisher Scientific Baltics UAB Use as component of buffer solutions for the production of purified proteins (cell extraction, chromatographic purification and solvent exchange) and in-process and final Quality Control testing; intended for use as laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications at Thermo Fisher Scientific Baltics UAB Commission decided Details
0206-02 Initial 4-Nonylphenol, branched and linear, ethoxylated - - Phadia GmbH; Thermo Fisher Scientific Baltics UAB Use as component of buffer solutions for the production of purified proteins (cell extraction, chromatographic purification and solvent exchange) and in-process and final Quality Control testing; intended for use as laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications at Thermo Fisher Scientific Baltics UAB Commission decided Details
0108-02 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 ORGAPHARM Use as an process solvent in the manufacture of an Active Pharmaceutical Ingredient: Nefopam hydrochloride Commission decided Details
0110-01 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 Bayer AG [application transferred from original applicant: Bayer Pharma AG, due to a notified legal entity change] Use as an industrial solvent in the manufacture of the high-grade pure final intermediate of Iopromide, the Active Pharmaceutical Ingredient for the X-ray contrast medium Ultravist® Commission decided Details
0081-01 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 Rafineria Gdańska Sp. z o.o. [name of applicant in the original application: GRUPA LOTOS S.A. updated due to a notified legal entity change] Use as an extraction solvent in the de-waxing of petroleum vacuum distillates and de-asphalted oil and de-oiling of slack wax for the production of base oils and paraffinic waxes. Commission decided Details
0022-01 Initial Trichloroethylene 201-167-4 79-01-6 SPOLANA a.s. Use as an extraction solvent in caprolactam production Commission decided Details
0129-01 Review report Trichloroethylene 201-167-4 79-01-6 SPOLANA s.r.o. [name of applicant in the original application: SPOLANA a.s. updated due to a notified change of corporate name] Use as an extraction solvent in caprolactam production Commission decided Details
0354-01 Review report Chromium trioxide 215-607-8 1333-82-0 Airbus Helicopters Technik GmbH Use as a surface hardener (functional chrome plating) in the manufacture of helicopter transmissions and the maintenance of helicopters. Opinion development Details
0107-01 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 emp Biotech GmbH Use as a solvent in manufacture of polymeric particles for pharmaceutical and research purification processes Commission decided Details
0227-01 Review report Trichloroethylene 201-167-4 79-01-6 ROQUETTE Frères Use as a processing aid in the biotransformation of starch to obtain betacyclodextrin Commission decided Details
0108-01 Initial 1,2-Dichloroethane (EDC) 203-458-1 107-06-2 ORGAPHARM Use as a process solvent in the manufacture of an Active Pharmaceutical Ingredient: Flecainide acetate Commission decided Details
0278-01 Review report Bis(2-methoxyethyl) ether 203-924-4 111-96-6 PMC ISOCHEM Use as a process solvent in one step of manufacturing of an active pharmaceutical ingredient used in an anti-protozoal drug Opinions adopted Details
0194-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Instrumentation Laboratory SpA Use as a lysing agent for red blood cells in blood analysis diagnostic device. Commission decided Details
0242-01 Review report Trichloroethylene 201-167-4 79-01-6 Microporous GmbH Trichloroethylene used as extraction solvent in the manufacture of polyethylene separators for lead-acid batteries Opinions adopted Details
0016-01 Initial Trichloroethylene 201-167-4 79-01-6 Microporous GmbH Trichloroethylene used as degreasing solvent in the manufacture of polyethylene separators for lead-acid batteries Commission decided Details
0017-01 Initial Trichloroethylene 201-167-4 79-01-6 ENTEK International Limited – [Decision discontinued as of 01/01/2021] Trichloroethylene as an extraction solvent for removal of process oil and formation of the porous structure in polyethylene based separators used in lead-acid batteries Discontinued as of 01 January 2021 Details
0363-01 Initial Chromium trioxide 215-607-8 1333-82-0 Ramboll Belgium BVBA (Indestructible Paints) Treatment of components used in industrial gas turbines and associated components using slurry coating products containing chromium trioxide to enhance corrosion resistance, chemical resistance, high temperature oxidation resistance, adhesion to components which produce a smooth finish and enhance the technical performance of turbines. Opinion development Details
0069-01 Initial Chromium trioxide 215-607-8 1333-82-0 Topocrom GmbH TOPOCROM functional chrome plating in closed reactor systems for the establishment of adjustable hemispherical surface structures. Commission decided Details
0031-01 Initial Sodium dichromate 234-190-3
7789-12-0
10588-01-9
Boliden Mineral AB The use of sodium dichromate in copper/lead separation in concentrators handling complex sulphide ores Commission decided Details
0104-01 Initial Sodium dichromate 234-190-3
7789-12-0
10588-01-9
Borealis Plastomers B.V. The use of sodium dichromate as in-situ corrosion inhibitor in a closed water/ammonia absorption cooling system Commission decided Details
0030-01 Initial Sodium chromate 231-889-5 7775-11-3
  • Dometic GmbH
  • Dometic Hűtőgépgyártó és Kereskedelmi Zrt.
The use of sodium chromate as an anticorrosion agent of the carbon steel cooling system in absorption refrigerators up to 0.75% by weight (Cr6+) in the cooling solution Commission decided Details
0210-02 Initial Chromium trioxide 215-607-8 1333-82-0 C. Hübner GmbH The use of chromium trioxide in the selective etching of multi-component (2K/3K) plastic articles. Opinions adopted Details
0210-03 Initial Chromium trioxide 215-607-8 1333-82-0 C. Hübner GmbH The use of chromium trioxide in the functional electroplating of single-component (1K) and multi-component (2K/3K) plastic articles with the specific aim of obtaining a final Cr(0) coating with high durability and chemical resistance while preserving the lightweight nature of the plastic component. Opinions adopted Details
0210-01 Initial Chromium trioxide 215-607-8 1333-82-0 C. Hübner GmbH The use of chromium trioxide in the etching of single-component (1K) plastic articles. Opinions adopted Details
0103-01 Initial Chromium trioxide 215-607-8 1333-82-0 Euro Cryospace France The use of chromium trioxide for the surface preparation of aluminium alloy cryogenic tanks used in the Ariane 5 launcher Commission decided Details
0271-01 Initial Chromium trioxide 215-607-8 1333-82-0 Villeroy & Boch Gustavsberg AB FM Mattsson Mora Group AB The use of chromium trioxide for electroplating of metal substrates with the purpose to create a long-lasting high durability surface with bright look for kitchen and bathroom sanitary ware Opinions adopted Details
0114–01 Initial Chromium trioxide 215-607-8 1333-82-0 Hansgrohe SE The use of chromium trioxide for electroplating of different types of substrates with the purpose to create a long-lasting high durability surface with bright (shiny) or matte look (Functional plating with decorative character) Commission decided Details
0034-01 Initial Chromium trioxide 215-607-8 1333-82-0 Grohe AG The use of Chromium trioxide for electroplating of different types of substrates with the purpose to create a long-lasting high durability surface with bright (shiny) or matte look (Functional electroplating with decorative character) Commission decided Details
0114–02 Initial Chromium trioxide 215-607-8 1333-82-0 Hansgrohe SE The use of chromium trioxide for a pre-treatment step (etching) in the electroplating process Commission decided Details
0034-02 Initial Chromium trioxide 215-607-8 1333-82-0 Grohe AG The use of Chromium Trioxide for a pre-treatment step (etching) in the electroplating process Commission decided Details
0250-01 Initial Chromium trioxide 215-607-8 1333-82-0 Tenneco Automotive Ibérica The use of Chromium Trioxide (EC 215-607-8) by Tenneco Automotive Ibérica S.A in the functional chrome plating of shock absorber rods. Opinions adopted Details
0251-01 Initial Chromium trioxide 215-607-8 1333-82-0 Tenneco Automotive Europe BVBA The use of Chromium Trioxide (EC 215-607-8) by Tenneco Automotive Europe BVBA in the functional chrome plating of shock absorber rods. Opinions adopted Details
0252-01 Initial Chromium trioxide 215-607-8 1333-82-0 Tenneco Automotive Eastern Europe Sp. z o.o. The use of Chromium Trioxide (EC 215-607-8) by Tenneco Automotive Eastern Europe Sp. z o.o. in the functional chrome plating of shock absorber rods. Opinions adopted Details
0249-01 Initial Chromium trioxide 215-607-8 1333-82-0 Monroe Czechia s.r.o. The use of Chromium Trioxide (EC 215-607-8) by Monroe Czechia s.r.o. in the functional chrome plating of shock absorber rods. Opinions adopted Details
0228-01 Initial Chromium trioxide 215-607-8 1333-82-0 Eaton S.R.L; Eaton Automotive Systems sp.zoo The use of Chromium Trioxide (EC 215-607-8) by Eaton Vehicle Group (Eaton) across two legal entities in the functional chrome plating of engine valves and valve actuation (“lash adjusters”) Commission decided Details